These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23329660)

  • 1. Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies.
    Nayak TK; Bernardo M; Milenic DE; Choyke PL; Brechbiel MW
    Radiology; 2013 Apr; 267(1):173-82. PubMed ID: 23329660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.
    Nayak TK; Garmestani K; Milenic DE; Baidoo KE; Brechbiel MW
    PLoS One; 2011 Mar; 6(3):e18198. PubMed ID: 21464917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab.
    Nayak TK; Garmestani K; Milenic DE; Brechbiel MW
    J Nucl Med; 2012 Jan; 53(1):113-20. PubMed ID: 22213822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
    Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
    Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
    Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
    J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.
    Pastuskovas CV; Mundo EE; Williams SP; Nayak TK; Ho J; Ulufatu S; Clark S; Ross S; Cheng E; Parsons-Reponte K; Cain G; Van Hoy M; Majidy N; Bheddah S; dela Cruz Chuh J; Kozak KR; Lewin-Koh N; Nauka P; Bumbaca D; Sliwkowski M; Tibbitts J; Theil FP; Fielder PJ; Khawli LA; Boswell CA
    Mol Cancer Ther; 2012 Mar; 11(3):752-62. PubMed ID: 22222630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma.
    Nayak TK; Garmestani K; Baidoo KE; Milenic DE; Brechbiel MW
    J Nucl Med; 2010 Jun; 51(6):942-50. PubMed ID: 20484421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
    McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
    J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Science to practice: Molecular targeting with SPECT/CT and MR imaging in oncology--integration of functional and structural imaging.
    Subramaniam RM
    Radiology; 2013 Apr; 267(1):1-3. PubMed ID: 23525713
    [No Abstract]   [Full Text] [Related]  

  • 10. Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor.
    Chang AJ; De Silva RA; Lapi SE
    Mol Imaging; 2013; 12(1):17-27. PubMed ID: 23348788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma.
    Belin LJ; Ady JW; Lewis C; Marano D; Gholami S; Mojica K; Eveno C; Longo V; Zanzonico PB; Chen NG; Szalay AA; Fong Y
    Surgery; 2013 Sep; 154(3):486-95. PubMed ID: 23890748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
    Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
    Razumienko EJ; Scollard DA; Reilly RM
    J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
    Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
    Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistribution and Tumor Uptake of
    Izquierdo-Sánchez V; Muñiz-Hernández S; Vázquez-Becerra H; Pacheco-Yepez J; Romero-Piña ME; Arrieta O; Medina LA
    Molecules; 2018 Nov; 23(12):. PubMed ID: 30501113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.
    Zhou Z; Vaidyanathan G; McDougald D; Kang CM; Balyasnikova I; Devoogdt N; Ta AN; McNaughton BR; Zalutsky MR
    Mol Imaging Biol; 2017 Dec; 19(6):867-877. PubMed ID: 28409338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
    Palm S; Enmon RM; Matei C; Kolbert KS; Xu S; Zanzonico PB; Finn RL; Koutcher JA; Larson SM; Sgouros G
    J Nucl Med; 2003 Jul; 44(7):1148-55. PubMed ID: 12843231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
    Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
    J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.